Vaxcyte, Inc. (NASDAQ:PCVX) Shares Acquired by Deutsche Bank AG

Deutsche Bank AG grew its position in Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) by 5.6% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,212,706 shares of the company's stock after acquiring an additional 64,522 shares during the period. Deutsche Bank AG owned about 0.97% of Vaxcyte worth $99,272,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Duquesne Family Office LLC raised its position in shares of Vaxcyte by 100.8% during the 4th quarter. Duquesne Family Office LLC now owns 86,265 shares of the company's stock worth $7,062,000 after purchasing an additional 43,300 shares during the last quarter. Crestline Management LP grew its stake in Vaxcyte by 88.6% during the 4th quarter. Crestline Management LP now owns 101,035 shares of the company's stock valued at $8,271,000 after acquiring an additional 47,452 shares in the last quarter. Brevan Howard Capital Management LP grew its stake in Vaxcyte by 137.8% during the 4th quarter. Brevan Howard Capital Management LP now owns 4,393 shares of the company's stock valued at $360,000 after acquiring an additional 2,546 shares in the last quarter. Bridgefront Capital LLC grew its stake in Vaxcyte by 4.2% during the 4th quarter. Bridgefront Capital LLC now owns 4,244 shares of the company's stock valued at $347,000 after acquiring an additional 172 shares in the last quarter. Finally, Brown Advisory Inc. grew its stake in Vaxcyte by 25.3% during the 4th quarter. Brown Advisory Inc. now owns 556,209 shares of the company's stock valued at $45,531,000 after acquiring an additional 112,170 shares in the last quarter. Institutional investors and hedge funds own 96.78% of the company's stock.

Analyst Ratings Changes

Several analysts recently issued reports on PCVX shares. Needham & Company LLC reaffirmed a "buy" rating and set a $90.00 price objective on shares of Vaxcyte in a research note on Tuesday, April 8th. Guggenheim restated a "buy" rating and set a $160.00 price target on shares of Vaxcyte in a report on Wednesday, March 12th. The Goldman Sachs Group cut their price target on shares of Vaxcyte from $138.00 to $100.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Bank of America cut their price target on shares of Vaxcyte from $157.00 to $137.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Finally, Evercore ISI upgraded shares of Vaxcyte to a "strong-buy" rating in a report on Monday, March 31st. Nine research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $136.50.

Vaxcyte Trading Up 3.1%

Shares of PCVX stock traded up $0.95 during trading hours on Friday, hitting $31.85. The company's stock had a trading volume of 1,522,478 shares, compared to its average volume of 1,338,366. The business has a fifty day moving average of $42.56 and a 200-day moving average of $71.71. The stock has a market cap of $4.11 billion, a price-to-earnings ratio of -6.92 and a beta of 1.27. Vaxcyte, Inc. has a twelve month low of $27.66 and a twelve month high of $121.06.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last announced its quarterly earnings data on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter last year, the firm earned ($0.85) EPS. On average, equities analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current fiscal year.

Insider Activity

In related news, COO Jim Wassil sold 8,000 shares of Vaxcyte stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $73.27, for a total transaction of $586,160.00. Following the sale, the chief operating officer now owns 154,931 shares of the company's stock, valued at $11,351,794.37. The trade was a 4.91% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 3.10% of the company's stock.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.